---
$id: https://graph.org.ai/products/commodity/51241126
$type: Product
source: UNSPSC
code: "51241126"
title: "Brimonidine"
class: "51241100"
classTitle: "Ophthalmic agents"
family: "51240000"
familyTitle: "Drugs affecting the ears, eye, nose and skin"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Brimonidine

**UNSPSC Code**: 51241126
**Class**: [Ophthalmic agents](Ophthalmic agents.mdx)
**Family**: [Drugs affecting the ears, eye, nose and skin](../Drugs affecting the ears, eye, nose and skin.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an anti-glaucoma agent and alpha-adrenergic agonist with the molecular formula C11H10BrN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E6GNX3HHTE, chemically known as 6-quinoxalinamine, 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)- (9ci) but generally known as brimonidine, which bears US NIH Compound Identifier 2435. Brimonidine most often comes in base and tartrate forms. European Medicines Agency schedules Brimonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05889MIG. The term BRIMONIDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules brimonidine in its Anatomical Therapeutic Chemical (ATC) Classification. BRIMONIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brimonidine under HS 29332990 and SITC 51573. As of Q4 2014, BRIMONIDINE remains the US FDA Preferred Term for this commodity. Brimonidine bears US NLM identifiers UMLS ID C0525227 and NCI Concept Code C65269. SMILES: C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)BR.

